Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vanda Pharmaceuticals Inc. - Common Stock (NQ:VNDA)

8.035 -0.785 (-8.90%)
Streaming Delayed Price Updated: 11:21 AM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vanda Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
A Glimpse of Vanda Pharma's Earnings Potential ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Forecasting The Future: 5 Analyst Projections For Vanda Pharmaceuticals ↗
 
Via Benzinga
News headline image
The Analyst Verdict: Vanda Pharma In The Eyes Of 5 Experts ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 13, 2025 ↗
 
Via Benzinga
News headline image
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
A Glimpse Into The Expert Outlook On Vanda Pharma Through 4 Analysts ↗
 
Via Benzinga
News headline image
FDA Unveils Grounds For Rejecting Vanda Pharmaceuticals Stomach Paralysis Candidate ↗
FDA denies Vanda's Tradipitant application for gastroparesis, urging new trials for efficacy and safety. Vanda disputes the agency's review process. 
Via Benzinga
News headline image
Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
Over 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst ↗
HC Wainwright initiates Buy on Vanda Pharmaceuticals with an $18 price target, citing undervaluation, a strong product portfolio, and growth in neurology. 
Via Benzinga
News headline image
Why Vanda Pharmaceuticals Stock Sank by Nearly 6% Today ↗
A regulator's decision drained the market's enthusiasm for the company. 
Via The Motley Fool
News headline image
FDA Strikes Off Vanda Pharmaceuticals' Tradipitant For Stomach Paralysis, Asks For Additional Studies ↗
The FDA rejected Vanda Pharmaceuticals' new drug application for tradipitant to treat gastroparesis, citing the need for more studies despite delays in its review process. Vanda argues the drug meets... 
Via Benzinga
News headline image
Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment
New research suggests that powerful magnets could effectively treat bipolar disorder. This therapy, which is known as accelerated intermittent theta burst stimulation (iTBS), uses magnetic waves... 
Via PressReach
News headline image
What's Going On With Vanda Pharmaceuticals Shares Today? ↗
Vanda Pharmaceuticals shares decline as Future Pak withdraws acquisition offer following Vanda's rejection and lack of response. 
Via Benzinga
News headline image
Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Tesla, Nvidia, John Wiley & Sons And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
S&P 500 Edges Lower; J. M. Smucker Shares Surge Following Earnings Beat ↗
 
Via Benzinga
Topics Stocks
News headline image
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Crude Oil Jumps 2%; Lululemon Posts Upbeat Earnings ↗
 
Via Benzinga
News headline image
Vanda Pharmaceuticals Receives Another Takeover Proposal, Considers $466M Deal ↗
Cycle Pharmaceuticals wants to acquire Vanda Pharmaceuticals for $8 per share, or $466 million. Cycle focuses on rare neurological conditions. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
Pre-market stock movers are worth checking out on Thursday morning as we dive into all of the hottest news affecting shares this morning! 
Via InvestorPlace
News headline image
Exact Sciences Reports Q1 Loss, Joins Beyond Meat, Duolingo And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
VNDA Stock Earnings: Vanda Pharma Misses EPS, Misses Revenue for Q1 2024 ↗
VNDA stock results show that Vanda Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda Pharmaceuticals
From Shareholder Capital LLC
Via GlobeNewswire
News headline image
US Supreme Court Declines To Hear Vanda Pharmaceuticals' Case Regarding Invalidation Of Patents For Its Sleep Disorder Drug, Hetlioz ↗
"Supreme Court denies review of Vanda Pharmaceuticals' patent revival attempt for Hetlioz sleep-disorder medication. Legal battle details, implications, and market impact." 
Via Benzinga
Topics Intellectual Property
News headline image
Crude Oil Dips 3%; U.S. Bancorp Profit Tops Views ↗
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Wednesday. The Dow traded up 0.04% to 37,813.77 while the NASDAQ fell 0.78% to 15,742.21.... 
Via Benzinga
Topics Stocks
News headline image
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.